[
  {
    "ts": null,
    "headline": "5 Years After Covid Hit: What Has Changed?",
    "summary": "5 Years After Covid Hit: What Has Changed?",
    "url": "https://finnhub.io/api/news?id=fa7e7eeddfcb063e6bef1d70603d79f4f5b6ea04abbed5dfb1b3905ecff3f0e6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741982760,
      "headline": "5 Years After Covid Hit: What Has Changed?",
      "id": 133219647,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "5 Years After Covid Hit: What Has Changed?",
      "url": "https://finnhub.io/api/news?id=fa7e7eeddfcb063e6bef1d70603d79f4f5b6ea04abbed5dfb1b3905ecff3f0e6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits",
    "summary": "Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious discrimination and executive pay structures, with the company advising shareholders to vote against these proposals at the forthcoming annual meeting. This may be part of what influenced Pfizer's share price movement by 0.3% over the past month, during a period that saw positive clinical trial results announced. The market overall has seen turbulence, with major indexes like the...",
    "url": "https://finnhub.io/api/news?id=0a300f5feaa754dd85b0020e6b8b8d07270c5238b85f9474dc6b0eb44404151a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741973700,
      "headline": "Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits",
      "id": 133185254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious discrimination and executive pay structures, with the company advising shareholders to vote against these proposals at the forthcoming annual meeting. This may be part of what influenced Pfizer's share price movement by 0.3% over the past month, during a period that saw positive clinical trial results announced. The market overall has seen turbulence, with major indexes like the...",
      "url": "https://finnhub.io/api/news?id=0a300f5feaa754dd85b0020e6b8b8d07270c5238b85f9474dc6b0eb44404151a"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Alert: Searches spiking for these stocks today",
    "summary": "These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Thera",
    "url": "https://finnhub.io/api/news?id=14c180e0f443d7173b9a6e7a336d4d3e0676e31456dea7f7ad005a6eda21d039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741968925,
      "headline": "Biotech Alert: Searches spiking for these stocks today",
      "id": 133185255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Thera",
      "url": "https://finnhub.io/api/news?id=14c180e0f443d7173b9a6e7a336d4d3e0676e31456dea7f7ad005a6eda21d039"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J",
    "summary": "Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=f5d184424f3a70056a265d54b281a19799cbf7d64a313a9fb5288b112358e934",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741963080,
      "headline": "The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J",
      "id": 133185257,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=f5d184424f3a70056a265d54b281a19799cbf7d64a313a9fb5288b112358e934"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Facing A First-Quarter Slowdown. Is Pfizer Stock Now A Sell?",
    "summary": "Is Pfizer stock a sell now with expectations for first-quarter sales and earnings to slide? Is PFE stock now a sell?",
    "url": "https://finnhub.io/api/news?id=5723e382043c3a0fc48b4ad61624254cb3ab38373673ae394d7014ead80e988a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741953619,
      "headline": "Pfizer Is Facing A First-Quarter Slowdown. Is Pfizer Stock Now A Sell?",
      "id": 133185258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Is Pfizer stock a sell now with expectations for first-quarter sales and earnings to slide? Is PFE stock now a sell?",
      "url": "https://finnhub.io/api/news?id=5723e382043c3a0fc48b4ad61624254cb3ab38373673ae394d7014ead80e988a"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).",
    "url": "https://finnhub.io/api/news?id=69f320a470a4404d3310a14540a67ad22f533ecb7fe437b1ed3f819aa2ec3b95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741942874,
      "headline": "Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks",
      "id": 133184268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).",
      "url": "https://finnhub.io/api/news?id=69f320a470a4404d3310a14540a67ad22f533ecb7fe437b1ed3f819aa2ec3b95"
    }
  }
]